Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Vaccine|June 9, 2006
Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1Charani Ranasinghe, Jill C Medveczky, Donna Woltring, et al.
Frontiers in Cellular and Infection Microbiology|April 20, 2019
Toward DNA-Based T-Cell Mediated Vaccines to Target HIV-1 and Hepatitis C Virus: Approaches to Elicit Localized Immunity for ProtectionZelalem A Mekonnen, Branka Grubor-Bauk, Makutiro G Masavuli, et al.
Vaccines|January 27, 2021
Adjuvant Selection for Influenza and RSV Prefusion Subunit VaccinesAriel Isaacs, Zheyi Li, Stacey T M Cheung, et al.
Vaccine|June 21, 2005
Development of a synthetic consensus sequence scrambled antigen HIV-1 vaccine designed for global useScott A Thomson, Angel B Jaramillo, Maryanne Shoobridge, et al.
Vaccine|June 30, 2005
Mucosally-administered human-simian immunodeficiency virus DNA and fowlpoxvirus-based recombinant vaccines reduce acute phase viral replication in macaques following vaginal challenge with CCR5-tropic SHIVSF162P3Stephen J Kent, C Jane Dale, Charani Ranasinghe, et al.
Ebiomedicine|October 21, 2023
Long-term safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2 in adults aged 18-55 years or ≥56 years: 12-month results from a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Journal of Infectious Diseases|November 24, 2025
Safety and immunogenicity of a SARS-CoV-2 spike, subunit vaccine stabilised in the prefusion conformation by second generation Molecular Clamp evaluated in adults aged 18-55 years: a randomised, double-blind, active comparator, Phase I trialKeith J Chappell, Francesca L Mordant, Alberto A Amarilla, et al.
The Lancet. Infectious Diseases|April 22, 2021
Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J Chappell, Francesca L Mordant, Zheyi Li, et al.
Clinical & Translational Immunology|April 12, 2021
Preclinical development of a molecular clamp-stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2Daniel Watterson, Danushka K Wijesundara, Naphak Modhiran, et al.
Pageof 5